Introduction {#Sec1}
============

The management of metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) is an intriguing challenge for oncologists, as the optimal integration of systemic and locoregional treatments may maximise survival outcomes and even cure a selected subgroup of patients. In the last years, the availability of active systemic treatments and the development of innovative surgical techniques have increased the percentage of potentially resectable patients, thus widening the horizons of pursuable surgical strategies.

Recent guidelines recommend the choice of highly active regimens, able to induce early and deeper tumour shrinkage, as the preferable options for patients with initially unresectable or borderline resectable colorectal cancer liver metastases (CRCLM).^[@CR1]--[@CR3]^ Therefore, doublets plus an anti-EGFR monoclonal antibody (only in *RAS* wild-type patients) or the triplet FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) plus bevacizumab (independently from molecular subgroups) are the standard regimens with highest activity.^[@CR4]--[@CR7]^ Recent data from phase II studies suggest that the combination of triplet chemotherapy with an anti-EGFR agent is feasible and allows achieving impressive response outcomes in molecularly selected patients.^[@CR8]--[@CR10]^

Although response parameters including early tumour shrinkage and deepness of response highly influence the chance to achieve R0 resections, the balance of several clinical, molecular and pathologic factors may influence patients' survival outcomes. Among these latter factors, the histopathologic response to the pre-operative treatment, mainly defined in terms of tumour regression grade (TRG), is crucial.^[@CR11]--[@CR15]^ Therefore, the optimal systemic regimen in the setting of liver-limited mCRC should be able to induce not only radiologic, but also histopathologic response. Retrospective studies suggested that the addition of bevacizumab to oxaliplatin-based doublets positively affects the rate of major/complete histopathologic response.^[@CR13],[@CR16],[@CR17]^ At the same time, up today no conclusive data about the differential impact of bevacizumab vs anti-EGFRs on TRG were provided, since available series are affected by several bias, including an inappropriate molecular selection of patients treated with anti-EGFRs, and the adoption of heterogeneous chemotherapy backbones.^[@CR18],[@CR19]^

Recently, three different histopathological growth patterns (HGPs) of liver metastases have been described: desmoplastic (i.e., with a capsule of stroma separating tumour and normal cells), pushing (i.e., with limited infiltration of normal hepatic plates by tumour cells), and replacement (i.e., with abundant infiltration of normal hepatic plates by tumour cells and vessel co-option).^[@CR20]^ From a biologic viewpoint, although metastases with desmoplastic and pushing HGPs rely on angiogenesis for their vascular supply, those with a replacement HGP co-opt pre-existing sinusoidal vessels, suggesting an intrinsically resistance to anti-angiogenic drugs.^[@CR21]^

Drawing from these considerations, we performed an extensive histopathologic evaluation of CRCLM resected after triplets and either bevacizumab or cetuximab, aiming at evaluating differences in histopathologic parameters of response according to administered targeted agents (bevacizumab vs cetuximab), assessing the independent prognostic impact of histopathologic parameters, and exploring the potential prognostic or predictive role of HGPs.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

From July 2008 to September 2016, 677 mCRC patients received first-line FOLFOXIRI or COI (capecitabine, oxaliplatin and irinotecan) plus bevacizumab or cetuximab in five clinical trials, enrolling patients from 40 Italian Oncology Units. All trials were approved by the local Ethics Committees at all participating centres, and patients provided their written informed consent to receive the treatment and to participate to translational analyses.

TRIBE (NCT00719797; (*N* = 508), 252 in the FOLFOXIRI plus bevacizumab arm),^[@CR22]^ MOMA (NCT02271464; *N* = 232)^[@CR23]^ and MACBETH (NCT02295930; *N* = 116)^[@CR10]^ by Gruppo Oncologico del Nord Ovest (GONO), adopted FOLFOXIRI as chemotherapy backbone; COI-E (EudraCT2008-001062-93; *N* = 31)^[@CR9]^ and COI-B (NCT02086656; *N* = 46)^[@CR24]^ by Fondazione IRCCS Istituto Nazionale dei Tumori (INT), used capecitabine, oxaliplatin, and irinotecan (COI). Bevacizumab was the combined targeted agent in TRIBE, MOMA, and COI-B, whereas cetuximab was used in MACBETH and COI-E. For the purpose of the present analysis, among patients treated with cetuximab, only those centrally defined as *RAS* and *BRAF* wild-type were included.

Trials by GONO included untreated mCRC patients, regardless their metastatic sites, with age between 18 and 75 years, ECOG PS of 2 or less (0 for patients between 71 and 75 years old), whose disease was deemed unresectable by experienced multidisciplinary teams. The adoption of guidelines for defining unresectability (i.e., Oncosurge criteria)^[@CR25]^ was highly recommended and multidisciplinary discussion of resectability was planned at the time of every disease re-assessment. FOLFOXIRI plus bevacizumab or modified FOLFOXIRI plus cetuximab were administered biweekly up to 12 cycles in the TRIBE trial and up to eight cycles in MOMA and MACBETH studies.

Trials by INT included only mCRC patients with borderline resectable liver-limited disease, defined by technical (tumour involvement of \>1 hepatic vein or \>4 hepatic segments, need for two-stage hepatectomy, portal vein embolisation or intraoperative radiofrequency ablation) and/or biologic reasons (≥4 metastatic nodules, synchronous metastases) predicting high recurrence risk. Four biweekly pre-operative cycles of COI-B or COI-E were planned.

In all studies, disease assessment by contrast-enhanced CT scan of chest and abdomen was performed every 8 weeks until disease progression.

For the purpose of this analysis, we identified patients with liver-limited disease who underwent secondary resection of their metastatic lesions with curative intent and with available tissue samples of resected metastases.

Histopathologic assessments {#Sec4}
---------------------------

All histopathologic assessments were performed by optical microscope and centralised at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Tissue samples were independently evaluated by two pathologists (MM, AP) blinded with respect to clinical information, treatment regimen, and outcome. TRG was scored according to the scheme from Mandard et al.,^[@CR26]^ then modified for liver metastases.^[@CR13]^ This score identifies five TRGs based on the presence of residual tumour cells and the extent of fibrosis. A cut-off of 3 mm of tumour thickness at the tumour-normal interface (TNI) was used to differentiate minor from major/complete pathologic response.^[@CR27]^

We distinguished infarct-like necrosis, consisting of large confluent areas of eosinophilic cytoplasmic remnants, located centrally within the lesion and surrounded by fibrosis and foamy macrophages, from tumoural "dirty" necrosis, containing nuclear debris in a patchy distribution.^[@CR28]^

Lymphocytic intratumoural infiltration and peritumoural inflammatory response were determined using a score ranging from absent (no lymphocytes) to mild (\<5 lymphocytes/HPF), moderate (5--10 lymphocytes/HPF), and severe (\>10 lymphocytes/HPF).^[@CR29],[@CR30]^

Toxicity-related parameters were evaluated in the non-neoplastic parenchyma and determined based on their presence or absence. Sinusoidal dilatation was graded semiquantitatively as follows: 0, absent; 1, mild (centrolobular involvement limited to one-third of the lobular surface); 2, moderate (centrolobular involvement extending to two-thirds of the lobular surface); 3, severe (complete lobular involvement).

The three common HGPs (desmoplastic, pushing and replacement) were recognised by standard H&E stained tissue sections, according to the key histopathologic characteristics of the growth patterns^[@CR20]^ (Supplementary Figure [1](#MOESM1){ref-type="media"}).

Statistics {#Sec5}
----------

Baseline characteristics and histopathologic parameters of response and toxicity reported in patients treated with triplet plus bevacizumab or triplet plus cetuximab were compared by means of *χ*^2^ test, Fisher exact test or Mann--Whitney test as appropriate.

RFS was calculated from the day of surgical resection to the evidence of disease relapse, or death from any cause. Post-resection OS was calculated from the day of surgical resection until death from any cause. Survival curves were estimated by the Kaplan--Meier method and compared with the log-rank test. The impact of histopathologic response and other prognostic factors on relapse-free survival (RFS) and post-resection overall survival (OS) was firstly assessed in univariate analyses. Significantly prognostic variables (*p* \< 0.10) were included in a multivariable Cox proportional hazard model.

We investigated the effects of clinical and molecular characteristics (sex, time between the diagnosis of CRC and the development of metastases, number of liver metastases and involved segments, lobar distribution of liver metastases, longest diameter of liver metastases, primary tumour location, prior primary resection, disease-free interval, CEA levels, *RAS*, and *BRAF* mutational status) and of radiologic response parameters (RECIST response, early response, and deepness of response^[@CR31]^ on the probability of achieving major histopathologic response in univariate analyses. Odds ratios (OR) and relative 95% confidence intervals (CIs) were calculated. Variables significantly (*p* \< 0.10) affecting the probability of undergoing liver surgery were included in a logistic regression model.

The efficacy of bevacizumab vs cetuximab in the different HGPs was assessed in terms of progression-free survival (PFS) that was calculated from the day of study entry (registration or randomisation) to the first observation of disease progression according to RECIST, or death from any cause.

Results {#Sec6}
=======

Liver metastases from 159 patients were analysed. Patients' baseline characteristics are summarised in Table [1](#Tab1){ref-type="table"}. Most of them had ECOG PS 0 (96%) and presented with synchronous liver metastases (82%). At the time of enrollment, in situ primary tumours were documented in 25% of patients. FOLFOXIRI and COI had been pre-operatively administered as chemotherapy backbones in 92 (58%) and 67 (42%) cases, respectively, and 103 (65%) and 56 (35%) patients had received bevacizumab and cetuximab as targeted agents (Supplementary Figure [2](#MOESM3){ref-type="media"}). With the obvious exception of the mutational status, no significant differences between the two treatment subgroups were reported. In the overall population, at a median follow up of 42.1 months, median RFS and median OS were 12.2 and 47.2 months, respectively.Table 1Patients' and disease characteristics in the overall population and according to treatment groupsOverall population *N* (%)Triplet + bev *N* (%)Triplet + cetuximab *N* (%)*pN* = 159*N* = 103*N* = 56Baseline characteristics Age (range)60 (23--75)61 (23--75)57 (32--70)--- ECOG PS  0152 (96)98 (95)54 (96)  1--27 (4)5 (5)2 (4)1.000 Sex   Male97 (61)63 (61)34 (61)   Female62 (39)40 (39)22 (39)1.000 Time to metastases   Synchronous131 (82)86 (83)45 (80)Metachronous28 (18)17 (17)11 (20)0.666 No. of liver metastases   ≥459 (37)42 (41)17 (30)   \<493 (59)58 / 5635 / 630.296   NA7 (4)3 (3)4 (7) Primary resected   No39 (25)22 (21)17 (30)   Yes120 (75)81 (79)39 (70)0.248 Location of primary tumour   Right colon40 (25)31 (30)9 (16)   Left colon64 (40)40 (39)24 (43)Extraperitoneal rectum52 (33)29 (28)23 (41)0.055   NA3 (2)3 (3)0 (0) Nodal status of primary tumour   Node positive85 (53)60 (59)25 (45)   Node negative35 (22)21 (20)14 (25)0.356   NA39 (25)22 (21)17 (30) Tumour size, diameter   \>5 cm56 (35)38 (37)18 (32)   ≤5 cm102 (64)65 (63)37 (67)0.603   NA1 (1)0 (0)1 (1) Distribution of liver metastases   Bilobar96 (60)63 (61)33 (60)   Unilobar54 (34)32 (31)22 (39)0.482   NA9 (6)8 (8)1 (1) No. of involved segments   ≥619 (12)13 (13)6 (11)   \<6116 (73)72 (70)44 (78)0.623   NA24 (15)18 (17)6 (11) Disease-free interval   \<12 months137 (86)90 (87)47 (84)   \>12 months22 (14)13 (13)9 (16)0.632 Mutational status *  RAS/BRAF* wt91 /(57)35 (34)56 (100) *  RAS* mut57 (36)57 (55)0 (0) *  BRAF* mut6 (4)6 (6)0 (0)**\<0.001**   NA5 (3)5 (5)0 (0)The \"p\" in bold indicate the p value statistically significant

Table [2](#Tab2){ref-type="table"} summarises the results in terms of histopathologic evaluations in the overall population and according to the two treatment subgroups. Pathologic complete response was detected in 7 (7%) and 1 (2%) case in the bevacizumab and in the cetuximab group, respectively (*p* = 0.436). In significantly higher percentages of cases in the bevacizumab than in the cetuximab group major histopathologic response (TRG1--2, 32 vs 14%, *p* = 0.013) and infarct-like necrosis (80 vs 64%, *p* = 0.035) were reported. No differences in other parameters of histopathologic response and toxicity were observed (Table [2](#Tab2){ref-type="table"}). In the bevacizumab group, no significant differences between *RAS* and *BRAF* wild-type cases and those bearing any *RAS* or *BRAF* mutation were evident (Supplementary Table [1](#MOESM2){ref-type="media"}), although all complete histopathologic responses occurred in *RAS*-mutated tumours.Table 2Histopathologic parameters in the overall population and according to treatment groupsOverall population *N* (%)Triplet + bev *N* (%)Triplet + cetuximab *N* (%)*pN* = 159*N* = 103*N* = 56Resection margins  R0133 (84)84 (82)49 (88)0.378  R126 (16)19 (18)7 (14)pCR  Yes8 (5)7 (7)1 (2)0.436  No151 (95)96 (93)55 (98)Histopathologic response  TRG18 (5)7 (7)1 (2)**0.013**  TRG233 (21)26 (25)7 (12)  TRG353 (33)33 (32)20 (36)  TRG449 (31)32 (31)17 (30)  TRG516 (10)5 (5)11 (20)  Major response (TRG1--2)41 (26)33 (32)8 (14)**0.015**  Partial response (TRG3)53 (33)33 (32)20 (36)  No response (TRG4--5)65 (41)37 (36)28 (50)Tumour-normal tissue interface  \<3 mm83 (52)59 (57)24 (43)0.082  \>3 mm76/4844 (43)32 (57)Necrosis  Mean494951  ≥40%27 (17)17 (17)10 (18)0.823  \<40%132 (83)86 (83)46 (92)Fibrosis  Mean232420  ≥40%110 (69)72 (70)38 (68)0.791  \<40%49 (31)31 (30)18 (32)Infarct-like necrosis  Yes118 (74)82 (80)36 (64)**0.035**  No41 (26)21 (20)20 (36)Lymphocitic infiltration  Absent22 (14)16 (16)6 (11)0.726  Mild119 (75)76 (74)43 (78)  Moderate17 (11)11 (10)6 (11)Peritumoural inflammatory response  Mild95 (60)58 (56)37 (66)0.373  Moderate60(38)41 (40)19 (34) Intense2 (1)2 (2)0 (0)  NA2 (1)2 (2)0 (0)Microvescicular steatosis  Yes108 (68)73 (71)35 (63)0.173  No48 (30)27 (26)21 (37)  NA3 (2)3 (3)0 (0)Macrovescicular steatosis  Yes72 (46)44 (43)28 (50)0.439  No85 (53)57 (55)28 (50)  NA2 (1)2 (2)0 (0)Sinusoidal dilatation  0 (absent)45 (29)28 (28)17 (30)0.932  1 (mild)56 (35)35 (34)21 (38)  2 (moderate)41 (25)28 (27)13 (23)  3 (severe)14 (9)9 (8)5 (9)  NE3 (2)3 (3)0 (0)Parenchimal necrosis  Yes14 (9)12 (11)2 (4)0.140  No141 (88)89 (87)52 (93)  NE4 (3)2 (2)2 (3)Pericellular fibrosis  Yes20 (12)16 (16)4 (7)0.112  No136 (86)84 (81)52 (93)  NE3 (2)3 (3)0 (0)The \"p\" in bold indicate the p value statistically significant

Among investigated baseline characteristics, radiologic response parameters and treatment subgroups, the administration of bevacizumab instead of cetuximab (OR = 2.83, 95% CI = 1.20--6.65; *p* = 0.015) and of FOLFOXIRI instead of COI (OR = 2.90, 95% CI = 1.30--6.44; *p* = 0.008), and the deepness of radiologic response (OR = 1.31, 95% CI = 1.07--1.60; *p* = 0.009) were significantly associated with the probability of achieving a major histopathologic response (Table [3](#Tab3){ref-type="table"}). In the multivariable model, including the three covariates, only the deepness of response (OR = 1.52, 95% CI = 1.38--1.94; *p* \< 0.001) and the administered targeted agent (OR = 6.00, 95% CI = 1.96--18.40; *p* = 0.002) were significantly associated with the probability of achieving a major response.Table 3Association of baseline characteristics and response parameters with the probability of achieving major histopathologic responseUnivariate analysisMultivariate analysis*N*%OR95% CI*p*OR95% CI*p*Baseline characteristics  Sex    Male9723.71---------------    Female6229.01.320.64--2.710.454---------  Time to metastases    Synchronous13125.21---------------    Metachronous2828.61.880.48--2.950.708---------  No. of liver metastases    ≥45927.11---------------    \<47428.41.060.50--2.290.862---------  Primary resected    No3836.81---------------    Yes12022.50.500.23--1.090.079---------  Location of primary    Right colon4027.51---------------    Left colon11625.00.880.39--1.980.752---------  Tumour size, diameter    \>5 cm5632.11---------------    ≤5 cm10222.50.610.30--1.270.188---------  Distribution of liver metastases    Bilobar9619.81---------------    Unilobar5429.61.710.79--3.690.171---------  No. of involved segments    \>61435.71---------------    ≤612127.30.680.21--2.160.536---------  Disease-free interval    \<12 mos2222.71---------------    \>12 mos13726.31.210.42--3.520.729---------  Mutational status    All wt9119.81---------------  *  RAS* mut5425.91.420.64--3.150.390---------  *  BRAF* mut633.32.030.34--11.950.600---------  Targeted agent    Cetuximab5614.31------1------    Bevacizumab10332.02.831.20--6.65**0.015**6.001.96--18.40**0.002**  Chemotherapy backbone    COI6714.91------1------    FOLFOXIRI9233.72.901.30--6.44**0.008**0.620.14--2.640.516Response parameters  RECIST response    No2416.71---------------    Yes13527.41.890.60--5.890.267---------  Early tumour shrinkage    No2313.01---------------    Yes12628.62.670.75--9.530.119---------  Deepness of response (per 10% increase)121---1.311.07--1.60**0.009**1.521.38--1.94**\<0.001**The \"p\" in bold indicate the p value statistically significant

Histopathologic response according to TRG was the only parameter associated with post-resection outcomes (Supplementary Table [2](#MOESM3){ref-type="media"}). In fact, when compared with patients reporting partial or no pathologic response (*N* = 118), those achieving major response (*N* = 41) showed significantly longer RFS (median RFS 21.0 vs 11.0 months, HR = 0.56, 95% CI = 0.40--0.89; *p* = 0.012) (Fig. [1a](#Fig1){ref-type="fig"}). As shown in Table [4](#Tab4){ref-type="table"}, when adjusting for clinical characteristics associated with RFS at univariate analyses, only the histopathologic response (HR = 0.41, 95% CI = 0.21--0.79; *p* = 0.008), as well as the nodal status of the primary tumour (HR = 0.50, 95% CI = 0.28--0.88; *p* = 0.018), retained its prognostic impact in the multivariable model.Fig. 1Kaplan--Meier estimates of RFS (**a**) and post-resection OS (**b**) according to the histopathologic response. Major response: TRG1--2; partial/no response: TRG3-4-5Table 4Association of baseline characteristics, treatment, and response parameters with relapse-free and overall survivalUnivariate analysisMultivariate analysis*pN*MedianHR for RFS (95% CI)*p*HR for RFS (95% CI)Baseline characteristics \>ECOG PS  015212.21---  1--2713.41.03 (0.39--2.76)0.953------ Time to metastases  Synchronous13111.011  Metachronous2819.80.59 (0.41--0.96)**0.034**0.95 (0.53--1.70)0.854 No. of liver metastases  ≥4599.311  \<49319.80.62 (0.40--0.91)**0.018**0.92 (0.49--1.72)0.804  NA7------ Primary resected  No399.711  Yes12013.80.61 (0.34--0.91)**0.020**0.50 (0.17--1.50)0.221 Location of primary tumour  Right colon4011.31---  Left colon11612.00.81 (0.52--1.23)0.301------  NA3--------- Nodal status of primary tumour  Node positive8512.611  Node negative3537.10.53 (0.36--0.85)**0.009**0.50 (0.28--0.88)**0.018**  NA39--------- Tumour size, diameter  \>5 cm5611.01---  ≤5 cm10212.71.00 (0.68--1.48)0.993------  NA1--------- Distribution of liver metastases  Bilobar9610.411  Unilobar5416.70.68 (0.47--1.01)**0.058**0.95 (0.52--1.72)0.864  NA9------ No. of involved segments  \>6199.21---  ≤611613.80.71 (0.32--1.37)0.273------  NA24--------- Disease-free interval  \<12 months13711.31---  \>12 months2213.30.88 (0.54--1.46)0.220------ Mutational status*  RAS/BRAF* wt9112.61---*  RAS* mut5712.70.93 (0.63--1.38)0.729------*  BRAF* mut62.41.99 (0.66--10.57)0.170------  NA5------ CEA  \<200 ng/ml11211.01---  \>200 ng/ml2113.80.91 (0.50--1.63)0.740------  NA26------ Treatment  Targeted agent  Cetuximab5610.41---  Bevacizumab10312.70.87 (0.59--1.27)0.463------ Targeted agent (wt only)  Cetuximab5610.41---  Bevacizumab3521.50.67 (0.41--1.14)0.151------ Chemotherapy backbone  FOLFOXIRI9216.711  COI6717.70.64 (0.45--0.94)**0.022**0.74 (0.44--1.26)0.277Response parameters RECIST response  \>No245.911  Yes13413.40.53 (0.29--0.97)**0.040**0.67 (0.36--1.28)0.231  NA1------ Early response  No234.91---  Yes12513.00.52 (0.23--0.72)**0.005**------  NA11------ Deepness of response  Per 10% increase121---0.96 (0.87--1.05)0.350------ Tumour regression grade  Partial/no histopathologic response (TRG3--4--5)11811.011  Major histopathologic response (TRG1--2)4121.00.56 (0.40--0.89)**0.012**0.41 (0.21--0.79)**0.008**  NA1--- Resection margins  R013312.71---  R12610.41.02 (0.63--1.67)**0.931**------Baseline characteristics ECOG PS  015246.011  1--2723.32.86 (1.19--31.75)**0.032**6.25 (0.67--58.09)0.109 Time to metastases  Synchronous13141.611  Metachronous28Undef0.53 (0.33--1.04)**0.068**0.97 (0.27--3.43)0.958 No. of liver metastases  ≥45934.811  \<49351.00.50 (0.29--0.83)**0.008**1.20 (0.32--4.41)0.789  NA7--------- Primary resected  No3933.411  Yes12044.60.59 (0.28--0.99)**0.051**0.84 (0.09--7.84)0.879Location of primary tumour  Right colon4042.71---  Left colon11643.20.96 (0.55--1.70)0.896---  NA3--------- Nodal status of primary tumour  Node positive8542.411  Node negative3558.60.54 (0.31--1.07)**0.080**0.45 (0.14--1.42)0.175  NA39--------- Tumour size, diameter  \>5 cm5636.51---  ≤5 cm10258.60.69 (0.40--1.14)0.143---  NA1--------- Distribution of liver metastases  Bilobar9636.51**1**  Unilobar5458.60.52 (0.32--0.91)**0.021**0.69 (0.24--1.98)0.496  NA9------ No. of involved segments  \>61933.41**1**  ≤611646.60.43 (0.11--0.79)**0.016**2.06 (0.36--11.89)0.422  NA24--------- Disease-free interval  \<12 months13742.41---  \>12 months2243.20.82 (0.43--1.61)0.589------ Mutational status*  RAS/BRAF* wt9146.011*  RAS* mut5742.71.16 (0.67--2.03)0.5801.77 (0.80--3.94)0.873*  BRAF* mut618.76.71 (2.36--180.20)**\<0.001**3.80 (0.30--210.50)0.632  NA5------ CEA  \<200 ng/ml11234.911  \>200 ng/ml2158.60.57 (0.22--1.10)**0.089**0.48 (0.15--1.54)0.220  NA26---------Treatment Targeted agent  Cetuximab5646.61---  Bevacizumab10342.41.21 (0.75--2.00)0.445------ Targeted agent (wt only)  Cetuximab5646.61---  Bevacizumab3534.81.08 (0.50--2.35)0.839------ Chemotherapy backbone  FOLFOXIRI9236.511  COI6764.30.52 (0.33--0.90)**0.019**0.94 (0.27--3.31)0.928 RECIST response  No2429.511  Yes13446.00.58 (0.23--1.13)**0.098**0.51 (0.17--1.55)0.239  NA1------ Early response  No2321.31---  Yes12546.00.45 (0.16--0.74)**0.006**------  NA11------ Deepness of response  Per 10% increase121---0.95 (0.84--1.06)0.343------ Histopathologic response  Partial/no response (TRG3--4--5)11842.111  Major response (TRG1--2)41Undef0.51 (0.32--0.99)**0.045**0.26 (0.07--0.89)**0.033**  NA1--- Resection margins  R013342.71  R12670.10.67 (0.37--1.34)0.284The \"p\" in bold indicate the p value statistically significant

Consistently, major response was associated with longer OS (median OS: unreached vs 42.1 months, HR = 0.51, 95% CI = 0.32--0.99; *p* = 0.045) (Fig. [1b](#Fig1){ref-type="fig"}). In the multivariable model (Table [4](#Tab4){ref-type="table"}), the histopathologic response was the only variable independently associated with OS (HR = 0.26, 95% CI = 0.07--0.89, *p* = 0.033).

Desmoplastic, pushing, and replacement HGPs were found in 28 (18%), 66 (41%), and 65 (41%) specimens, respectively. In the overall population, no impact of HPGs on survival parameters was observed (OS log-rank *p* = 0.856; RFS log-rank *p* = 0.783) (Fig. [2a, b](#Fig2){ref-type="fig"}), but a higher percentage of cases with desmoplastic HGP showed a major histopathologic response (57 vs 17% in pushing and 22% in replacement HGP, *p* \< 0.001). Although among patients whose metastases presented a desmoplastic HGPa non-significant advantage for cetuximab was reported (HR = 2.17, 95% CI = 0.89--5.48, *p* = 0.106; Fig. [2c](#Fig2){ref-type="fig"}), significantly longer RFS was achieved with bevacizumab than with cetuximab in the pushing subgroup (HR = 0.50, 95% CI = 0.25--0.84, *p* = 0.012; Fig. [2d](#Fig2){ref-type="fig"}). In the replacement subgroup, no differences between the two agents were reported (RFS: HR = 1.12, 95% CI = 0.63--2.04, *p* = 0.697) (Fig. [2e](#Fig2){ref-type="fig"}). Consistent results were achieved when the analyses were restricted to *RAS* and *BRAF* wild-type patients (Supplementary Figure [3a](#MOESM5){ref-type="media"}--[c](#MOESM5){ref-type="media"}). The association of HGPs with histopathologic response according to the administered targeted agent is described in the Supplementary Figure [4](#MOESM6){ref-type="media"}.Fig. 2Kaplan--Meier estimates of post-resection OS (**a**) and RFS (**b**) according to HGPs in the overall population and of RFS in the desmoplastic (**c**), pushing (**d**) and replacement (**e**) HGPs according to the administered targeted agent

Discussion {#Sec7}
==========

The landscape of CRCLM is extremely heterogeneous and multiple clinical, molecular, and pathological factors weight on patients' outcomes.^[@CR32]^ Because of the wide spectrum of potential clinical scenarios, both the design of clinical studies and the applicability of trials' results in the daily practice are extremely difficult. In fact, in spite of the limited amount of prospective evidence in this field, the management of patients with CRCLM has notably changed in the last decade, with a clinically meaningful absolute survival gain.^[@CR33]^ Not only the improvements in innovative surgical and other locoregional techniques, but also the availability of several conversion or neoadjuvant systemic regimens contributed to these advances, that are expected to further improve over time.^[@CR22],[@CR34]--[@CR37]^ Increasing evidence is collected about the possibility to significantly affect the natural history of the disease through a substantial pharmacological and surgical debulking of the tumour burden, made possible by the multidisciplinary management of affected patients.

To this regard, the pathologists' role in the multidisciplinary team is increasingly important, although further effort is needed to clarify how to exploit histopathologic parameters to drive treatment decisions. Here we confirm the impact of TRG on the post-operative outcome, while no association of necrosis, fibrosis and infarct-like necrosis with survival is reported.^[@CR11],[@CR13],[@CR15]--[@CR17]^

It is arguable that TRG mirrors the ability of pre-operative regimens to control the micrometastatic disease, thus reducing the probability to experience disease relapse.

Our data strengthen this concept, since the association between TRG and survival parameters is retained in the multivariable model, aiming at catching the heterogeneity of potential clinical presentations and previous responses to systemic treatments. As all patients included in the present analysis received a triplet plus a biologic as pre-operative treatment, it seems that the use of highly active regimens as conversion or neoadjuvant treatments may counterbalance the poor prognostic impact of negative baseline characteristics when achieving a radical resection of metastatic lesions. In other words, clinical and molecular factors weighing on post-resection outcomes are no longer relevant when using these upfront treatments. On the other side, achieving a relevant histopathologic response is a major determinant of clinical outcome and, notably, is significantly associated with deeper radiologic response. The possibility to adopt different post-operative strategies based on histopathologic response results is worth of investigation in properly designed prospective trials.

Here we also show that the use of triplets plus bevacizumab had more histopathologic responses than triplets plus cetuximab. Up today, whereas different retrospective analyses with several potential biases consistently suggested that the addition of bevacizumab to chemotherapy alone increases the rate of major histopathologic responses, conflicting results were provided with regard to the comparison of chemotherapy plus either bevacizumab or an anti-EGFR.^[@CR18],[@CR19]^ Notably, all these studies were invariably biased by their retrospective nature, the heterogeneity of chemotherapy backbones and the inappropriate molecular selection of patients treated with the anti-EGFRs.

Our effort suffers of some limitations. Firstly, trials included in our pooled analysis did not randomise between bevacizumab and cetuximab. However, inclusion criteria of these studies were perfectly superimposable, with the exception of the molecular selection for studies evaluating cetuximab-containing regimens, and the studies were conducted in the same timeframe. As a consequence, characteristics of enrolled patients were highly balanced in the two groups. Secondly, only patients with initially unresectable or borderline resectable but at high risk of recurrence are included, thus preventing from applying present results to easily resectable patients at low risk of recurrence. However, these patients are not candidate to receive biologic agents, and in particular anti-EGFRs since a potential detrimental effect with the addition of cetuximab to perioperative oxaliplatin-based doublets was evidenced.^[@CR33]^ Thirdly, although the homogeneity of chemotherapy backbones definitely represents a strong point of this analysis, 31 patients received capecitabine as part of the chemotherapy regimen, in combination with cetuximab. The association of fluoropyrimidines other than infusional 5-fluoruracil with anti-EGFR monoclonal antibodies is not recommended by current guidelines. Nevertheless, in the multivariable model the impact of the targeted agent on the probability of achieving a major histopathologic response is independent of the associated chemotherapy regimen. Finally, we were not able to provide formal demonstration that regimens able to determine better histopathologic responses favorably affect survival, thus failing to prove the surrogacy of TRG for OS, as other previous series in this field did.

The evaluation of CRCLM' HGPs has recently gained attention from the oncology perspective due to its potential prognostic and even predictive meaning, as well as its easy assessment in H&E stained slides.^[@CR20],[@CR21]^ The available retrospective literature suggests that replacement HGP may be associated with poorer prognosis, worse histopathologic response to neoadjuvant treatments and lack of survival benefit from the addition of bevacizumab to chemotherapy alone. To the best of our knowledge, this is the first attempt to potentially catch a differential benefit from bevacizumab vs cetuximab according to HGPs. Even if our series cannot provide definitive conclusions, interesting results about the better efficacy of bevacizumab and cetuximab in the pushing and in the desmoplastic patterns, respectively, were found and should be validated through properly designed randomised trials. The lack of prognostic impact of HGPs in the present series, differently from literature data, may be explained by the fact that the adopted highly active pre-operative regimens may have weakened the weight of poor prognostic factors including replacement HPG. A similar effect was previously shown by our group about the lack of negative impact of *BRAF* mutation in mCRC patients with LLD, resected after FOLFOXIRI plus bevacizumab.^[@CR7]^ Moreover, the use of systemic treatments may somehow change the percentage of a specific HGPs component in favor of another thus representing a potential confounding effect in our and previous studies, which mostly included patients treated in the pre-operative setting. Finally, assessing HGPs post-operatively clearly hampers its potential application to the choice of the pre-operative strategy. Therefore, to deepen and hopefully translate to clinical practice the predictive power of HGPs, additional valuable information should be prospectively obtained through liver biopsies performed before starting the conversion/neoadjuvant treatment. To this purpose, the possibility to classify accurately HGPs by means of pre-treatment imaging parameters should be investigated.
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